We propose that the TGFB2-promoted invasive growth of DIPG cells, their TGFB2-associated radiation resistance, and possibly TGFB2-mediated restrictions of the cellular anti-glioma immunity within the TME contribute to the observed adverse impact of high TGFB2 levels on the survival outcomes of DIPG patients. The gene discussed is TGFB2; the disease is diffuse intrinsic pontine glioma.